PROGRAM OVERVIEW

The identification of the estrogen receptor and the role it has in the development of most breast cancers has led to the development of endocrine therapies. In this Summit program, the faculty will explore these therapies with regard to clinical usage, efficacy, safety, and administration. This case-based program will allow participants to experience real-life examples of how these therapies may be used for HR+/HER2- metastatic breast cancer and inform learners how to tailor treatment individually and overcome endocrine resistance.

TARGET AUDIENCE

These educational activities are intended for medical oncologists, advanced practice providers, and pharmacists in both academic and community settings.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Appraise the key clinical findings for current and emerging endocrine therapies for patients with HR+/HER2- MBC
• Summarize the limitations of existing endocrine therapies for patients with HR+/HER2- MBC and their unmet treatment needs
• Utilize molecular testing methods to detect mutations in patients with HR+/HER2- MBC
• Assess tumor molecular mutation profiles to inform treatment selection for patients with HR+/HER2- MBC

PROGRAM FEATURES

• Downloadable whiteboard animation and shared decision-making video caseInteractive,
• Interactive case-based learning environment
• Create-your-own personalized poster